Skip to main content
SpringerLink
Log in

Development of Ligands for Receptor Imaging

  • Chapter
Advanced Imaging In Coronary Artery Disease

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 202))

  • 121 Accesses

Abstract

The noninvasive characterization of the cardiac nervous system by positron emission tomography (PET) may provide important pathophysiological information in various cardiac diseases. Changes in numbers of neurotransmitter receptors have been associated with myocardial ischemia and infarction, congestive heart failure, cardiomyopathy, as well as diabetes or thyroid-induced heart muscle disease. Knowledge on these receptor densities is based on post mortem or biopsy material. With PET it is possible to investigate the whole heart in vivo. A prerequisite for imaging of the cardiac nervous system is the availability of appropriate radioligands, which includes its radiolabeling and evaluation in animals and human volunteers. This chapter gives an overview of the process of development of a radioligand for the β-adrenergic receptor, which is illustrative for the development of radioligands in general.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Michel MC, Brodde OE, Insel PA. Peripheral adrenergic receptors in hypertension. Hypertension 1990; 16:107–20.

    Article  PubMed  CAS  Google Scholar 

  2. Brodde OE. Beta1-and beta2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991; 43: 203–42.

    PubMed  CAS  Google Scholar 

  3. Lands AM, Arnold A, McAuliff P, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597–8.

    Article  PubMed  CAS  Google Scholar 

  4. Watson S, Abbott A. TiPS receptor nomenclature supplement. Trends Pharmacol. Sci 1990; Suppl:1–30.

    PubMed  CAS  Google Scholar 

  5. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad. Sci. 1949; 51:660 72.

    Article  Google Scholar 

  6. Barnett DB, Rugg EL, Nahorski SR. Direct evidence of two types of beta-adrenoceptor binding site in lung tissue. Nature 1978; 273:166–8.

    Article  PubMed  CAS  Google Scholar 

  7. Minneman KP, Hegstrand LR, Molinoff PB. Simultaneous determination of beta-1 and beta-2 adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol 1979; 16:34–46.

    PubMed  CAS  Google Scholar 

  8. Bristow MR, Ginsburg R, Umans V, et al. Beta1-and beta2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta1-receptor down-regulation in heart failure. Circ Res 1986; 59:297–309.

    Article  PubMed  CAS  Google Scholar 

  9. Michel MC, Pingsmann A, Beckeringh JJ, Zerkowski HR, Doetsch N, Brodde OE. Selective regulation of beta1-and beta2-adrenoreceptors in the human heart by chronic β-adrenoreceptor antagonist treatment. Br J Pharmacol 1988; 94:685–92.

    Article  PubMed  CAS  Google Scholar 

  10. Eckelman WC. The application of receptor theory to receptor binding and enzyme-binding oncologic radiopharmaceuticals. Nucl Med Biol 1994; 21:759–69.

    Article  PubMed  CAS  Google Scholar 

  11. Van Waarde A, Elsinga PH, Anthonio RL, et al. Study of cardiac receptor ligands by positron emission tomography. In: Van der Wall EE, Blanksma PH, Niemeyer MG, Paans AM, editors. Cardiac positron emission tomography. Dordrecht: Kluwer Academic Publishers; 1995:171–82.

    Google Scholar 

  12. Elsinga PH, van Waarde A, Visser GM, Vaalburg W. Synthesis and preliminary evaluation of (R,S)-1-[2((carbamoyl-4-hydroxy)phenoxy)-ethylamino]-3-[4(1-[11C]-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol ([11C]CGP 20712A) as a selective beta-1 adrenoceptor ligand for PET. Nucl Med Biol 1994; 21:211–7.

    Article  PubMed  CAS  Google Scholar 

  13. Antoni G, Ulin J, Lângström B. Synthesis of the 11C-labelled beta-adrenergic receptor ligands atenolol, metoprolol and propranolol. Appl Radiât Isot 1989; 40:561–4.

    Article  CAS  Google Scholar 

  14. Prenant C, Sastre J, Crouzel C, Syrota A. Synthesis of [11C]pindolol. J Label Compd Radiopharm 1987; 24:227–32.

    Article  CAS  Google Scholar 

  15. Delforge J, Syrota A, Lançon JP, et al. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177 and a new graphical method [published erratum appear in J Nucl Med 1994; 32:739-48]. J Nucl Med 1991; 32:739–48.

    PubMed  CAS  Google Scholar 

  16. Merlet P, Delforge J, Syrota A, et al. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993; 87:1169–78.

    Article  PubMed  CAS  Google Scholar 

  17. Lefroy DC, De Silva R, Choudhury L, et al. Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol 1993; 22:1653–60.

    Article  PubMed  CAS  Google Scholar 

  18. Delforge J, Nakajima K, Syrota A, et al. PET investigation of beta-adrenergic receptors using CGP 12177 [abstract]. J Nucl Med 1989; 30:825.

    Google Scholar 

  19. Boullais C, Crouzel C, Syrota A. Synthesis of 4-(3-t-butylamino-2-hydroxy-propoxy)-benzimidazol-2[11C]-one (CGP 12177). J Label Compd Radiopharm 1985; 23:565–7.

    Article  Google Scholar 

  20. Brady F, Luthra SK, Tochon-Danguy H-J, et al. Asymmetric synthesis of a precursor for the automated radiosynthesis of S-(3′-t-butylamino-2′-hydroxypropoxy)-benzimidazol-2-[11C]one (S-[11C]CGP 12177) as a preferred radioligand for beta-adrenergic receptors. Appl Radiât Isot 1991; 42:620–8.

    Google Scholar 

  21. Aigbirhio F, Pike VW, Francotte E, et al. S-[1-(2,3-Diaminophenoxy)]-3′-(N-t-butylamino)propan-2′-ol-Simplified asymmetric synthesis with CD and chiral HPLC analysis. Tetrahedron Asymmetry 1992; 3:539–44.

    Article  CAS  Google Scholar 

  22. Van Waarde A, Visser TJ, Elsinga PH, et al. Imaging beta-adrenoceptors in the human brain with (S)-1′-[18F]fluorocarazolol. J Nucl Med 1997; 38:934–9.

    PubMed  Google Scholar 

  23. Zheng L, Berridge MS, Ernsberger P. Synthesis, binding properties and 18F labeling of fluorocarazolol, a high affinity beta-adrenergic receptor antagonist. J Med Chem 1994; 37:3219–30.

    Article  PubMed  CAS  Google Scholar 

  24. Elsinga PH, Vos MG, Van Waarde A, et al. (S,S)-and (S,R)-1′-[18F]fluorocarazolol, ligands for the visualization of pulmonary beta-adrenergic receptors with PET. Nucl Med Biol 1996; 23:159–67.

    Article  PubMed  CAS  Google Scholar 

  25. Berridge MS, Cassidy EH, Terris AH, Vesselle JM Preparation and in vivo binding of [11C]carazolol; a radiotracer for the beta-adrenergic receptor. Int J Rad Appl Instrum B 1992; 19:563–9.

    PubMed  CAS  Google Scholar 

  26. Berridge MS, Nelson AD, Zheng L, Leisure GP, Miraldi F. Specific beta-adrenergic receptor binding of carazolol measured with PET. J Nucl Med 1994; 35:1665–76.

    PubMed  CAS  Google Scholar 

  27. Van Waarde A, Elsinga PH, Brodde OE, Visser GM, Vaalburg W. Myocardial and pulmonary uptake of S-1′-[18F]fluorocarazolol in intact rats reflects radioligand binding to beta-adrenoceptors. Eur J Pharmacol 1995; 272:159–68.

    Article  PubMed  Google Scholar 

  28. Doze P, Van Waarde A, Elsinga PH, Van Loenen-Weemaes AM, Willemsen AT, Vaalburg W. Validation of S-1=-[18F]fluorocarazolol for in vivo imaging and quantification of cerebral β-adrenoceptors. J Cereb Blood Flow Metab. Submitted.

    Google Scholar 

  29. Visser Tl, Van Waarde A, Van der Mark TW, et al. Characterization of pulmonary and myocardial beta-adrenoceptors with S-1:-[fluorine

    Google Scholar 

  30. Elsinga PH, Van Waarde A, Jaeggi KA, Schreiber G, Heldoom M, Vaalburg W. Synthesis and evaluation of (S)-4-(3-(2=-[11C]-isopropylamino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ((S)-[11C]-CGP 12388) and (S)-4-(3-(1=-[18F]-fluoroisopropylamino)-2-hydroxypropoxy)-2H-benzimidazol-2-one((S)-[18F]fluoro-CGP 12388) for visualization of beta-adrenoceptors with positron emission tomography. J Med Chem 1997; 40:3829–35.

    Article  PubMed  CAS  Google Scholar 

  31. De Groot TJ, Van Waarde A, Elsinga PH, Visser GM, Brodde OE, Vaalburg W. Synthesis and evaluation of 1′-[18F]fluorometoprolol as a potential tracer for the visualization of beta-adrenoceptors with PET. Nucl Med Biol 1993; 20:637–42.

    Article  PubMed  Google Scholar 

  32. Van Waarde A, Elsinga PH, Doze P, Heldoorn M, Jaeggi KA, Vaalburg W. A novel beta-adrenoceptor ligand for PET: evaluation in experimental animals. Eur J Pharmacol. In press 1998.

    Google Scholar 

  33. Dolle F, Valette H, Hinnen S, Escargueil C, Crouzel C. Carbon-11 labeling and in vivo characterization of a highly selective cardiac β 1-adrenoceptor antagonist. Proceedings of the 12th Int Symp radiopharm Chem, Uppsala, Sweden, June 1997; 603–4.

    Google Scholar 

  34. Daemmgen JW, Engelhardt G, Pelzer H. Pharmacological properties of an extremely selective betal-adrenoceptor antagonist, 2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-3-methyl-6-methoxy-4(3H)-quinazoline ([+/-] HX-CH 44 BS). Arzneimittelforschung 1985; 35:383–90.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Philip H. Elsinga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aren van Waarde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ton J. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Willem Vaalburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiology, Leiden University Medical Center Leiden, Leiden, The Netherlands

    Ernst E. Van Der Wall

  2. Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands

    Paul K. Blanksma  & Harry J. G. M. Crijns  & 

  3. Department of Cardiology, Martini Hospital, Groningen, The Netherlands

    Menco G. Niemeyer

  4. PET-center, University Hospital Groningen, Groningen, The Netherlands

    Willem Vaalburg

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Elsinga, P.H., van Waarde, A., Visser, T.J., Vaalburg, W. (1998). Development of Ligands for Receptor Imaging. In: Van Der Wall, E.E., Blanksma, P.K., Niemeyer, M.G., Vaalburg, W., Crijns, H.J.G.M. (eds) Advanced Imaging In Coronary Artery Disease. Developments in Cardiovascular Medicine, vol 202. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0866-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-0866-2_19

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3746-4

  • Online ISBN: 978-94-007-0866-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation